Pharmaceutical Microbiology

Antimicrobial Resistance Mechanisms and Evolution

Investigation of genetic and biochemical pathways underlying drug resistance development in pathogenic microorganisms and strategies to combat resistance evolution.

RESEARCH GAP FRONTIERS

Biofilm Formation and Drug Penetration

Study of microbial biofilm architecture and matrix composition to understand how antibiotics fail to penetrate and eliminate sessile bacteria.

RESEARCH GAP FRONTIERS

Phage Therapy Development and Optimization

Engineering bacteriophages as therapeutic agents against antibiotic-resistant pathogens with focus on safety, efficacy, and clinical translation.

RESEARCH GAP FRONTIERS

Probiotics and Microbiome Engineering

Design and characterization of beneficial microbial consortia to restore dysbiotic microbiomes and prevent pathogenic colonization.

RESEARCH GAP FRONTIERS

Fungal Pathogenesis and Antifungal Development

Elucidation of virulence factors in pathogenic fungi and rational design of novel antifungal therapeutics with reduced host toxicity.

RESEARCH GAP FRONTIERS

Viral Mutation and Drug Escape Mechanisms

Analysis of viral quasispecies dynamics and mechanisms enabling rapid adaptation to antiviral drugs through high mutation rates.

RESEARCH GAP FRONTIERS

Combination Antibiotic Therapies

Investigation of synergistic and antagonistic interactions between multiple antimicrobial agents to optimize therapeutic efficacy.

RESEARCH GAP FRONTIERS

Mycobacterial Drug Resistance Pathways

Characterization of tuberculosis and non-tuberculous mycobacteria resistance to first and second-line drugs at molecular and genetic levels.

RESEARCH GAP FRONTIERS

Antimicrobial Peptides and Natural Products

Discovery, optimization, and mechanistic studies of peptide and plant-derived compounds with broad-spectrum antimicrobial activity.

Hospital-Acquired Infection Prevention

Investigation of nosocomial pathogen transmission routes and development of environmental and surface disinfection strategies.

Anaerobic Microbiology and Metabolism

Study of obligate and facultative anaerobic pathogens'' metabolic pathways and their susceptibility to antimicrobial agents.

Parasitic Infection Drug Targets

Identification and validation of essential parasite proteins as therapeutic targets for developing antiparasitic medications.

Vaccine Development and Immunogenicity

Design of microbial-based vaccines and assessment of immune responses to prevent infectious disease establishment.

Pharmacokinetics of Antimicrobial Agents

Quantitative analysis of drug absorption, distribution, metabolism, and elimination in the context of microbial infection treatment.

Efflux Pump Inhibition Strategies

Development of compounds that inhibit bacterial multidrug efflux pumps to restore antimicrobial agent efficacy.

Lipopolysaccharide and Gram-Negative Barriers

Structural and functional analysis of bacterial outer membranes and strategies to enhance antibiotic permeability in Gram-negative organisms.

Clinical Microbiology and Diagnostics

Development of rapid molecular and culture-based diagnostic methods for pathogen identification and susceptibility testing.

Sterilization and Preservation Methods

Optimization of sterilization techniques and pharmaceutical formulation strategies to prevent microbial contamination in drug products.

Quorum Sensing and Virulence Regulation

Investigation of bacterial cell-to-cell communication systems and development of quorum sensing inhibitors to attenuate pathogenicity.

Immunocompromised Host Infections

Study of opportunistic pathogen infections in immunocompromised patients and antimicrobial strategies for challenging clinical scenarios.

Nanomedicine for Antimicrobial Delivery

Engineering nanoparticles and liposomes as carriers for enhanced delivery of antimicrobial agents to infected tissues.

Horizontal Gene Transfer and Resistance Spread

Mechanisms of plasmid conjugation, transformation, and transduction facilitating rapid dissemination of resistance genes among bacterial populations.

Sexually Transmitted Infection Microbiology

Characterization of bacterial, viral, and parasitic STI pathogens and development of targeted antimicrobial interventions.

Respiratory Tract Infection Microbiology

Investigation of pulmonary pathogens and optimization of inhaled antimicrobial delivery systems for respiratory infections.

Urinary Tract Infection Pathogens

Study of uropathogenic bacteria and biofilm formation in urinary catheters with focus on preventing and treating UTIs.

Gastrointestinal Pathogen Control

Investigation of enteric pathogens and development of oral antimicrobial formulations resistant to gastric degradation.

Skin and Soft Tissue Infections

Characterization of dermatological pathogens and topical antimicrobial formulation design for enhanced skin penetration.

Bacterial Toxin Production and Neutralization

Study of exotoxin and enterotoxin mechanisms with development of toxin-neutralizing antibodies and inhibitors.

Antimicrobial Susceptibility Testing Methods

Standardization and advancement of broth microdilution, disk diffusion, and molecular susceptibility testing platforms.

Intracellular Pathogen Targeting

Development of antimicrobial agents capable of penetrating host cells to eliminate intracellular bacterial and parasitic pathogens.

Nosocomial Pathogen Epidemiology

Molecular epidemiological tracking of healthcare-associated pathogen clones and their antimicrobial resistance patterns.

Spore Germination and Disinfection

Investigation of bacterial spore resistance mechanisms and development of sporicide disinfectants for pharmaceutical manufacturing.

Immunomodulatory Microbial Therapies

Design of microbial derivatives and live biotherapeutics that enhance immune function to combat recurrent infections.

Endotoxin Detection and Removal

Development of rapid endotoxin assays and purification methods to ensure pharmaceutical safety and sterility.

Protein Synthesis Inhibitor Development

Design of novel antimicrobials targeting bacterial ribosomal machinery while minimizing eukaryotic mitochondrial toxicity.

Cell Wall Targeting Therapeutics

Development of agents targeting peptidoglycan synthesis and cell wall integrity in bacteria with reduced resistance potential.

Fungal Biofilm Eradication Strategies

Investigation of antifungal agent activity against Candida and Aspergillus biofilms in medical devices and tissues.

Antimicrobial Stewardship Programs

Development of clinical frameworks and metrics to optimize antimicrobial use and minimize resistance development.

Herpes Virus Reactivation Mechanisms

Characterization of latency and reactivation pathways in herpesviruses and development of suppressive antiviral strategies.

Bacterial Persistence and Dormancy

Investigation of persister cell formation and viable but nonculturable state enabling survival under antimicrobial stress.

Immunoglobulin-Based Antimicrobial Therapy

Development of monoclonal antibodies and immunoglobulin therapeutics targeting microbial virulence factors.

DNA Gyrase and Topoisomerase Inhibition

Design of next-generation fluoroquinolones and novel topoisomerase inhibitors with improved spectrum and reduced resistance.

Prion Disease Prevention and Treatment

Investigation of prion protein misfolding and development of anti-prion compounds for transmissible spongiform encephalopathies.

Mycotic Infection of Central Nervous System

Study of CNS fungal pathogenesis and development of antifungals with enhanced blood-brain barrier penetration.

Bacterial Adhesion and Surface Interactions

Characterization of pili, flagella, and adhesins mediating bacterial attachment and development of anti-adhesion therapeutics.

Tuberculosis Drug Development Pipeline

Design and testing of novel compounds against Mycobacterium tuberculosis with activity against multidrug-resistant strains.

Pharmaceutical Microbiota Analysis Methods

Development of next-generation sequencing and metagenomic approaches for microbial identification in pharmaceutical environments.

Antimicrobial Preservative Systems

Formulation and validation of preservative systems maintaining pharmaceutical product sterility throughout shelf life.

Metallo-Beta-Lactamase Inhibitor Discovery

Development of inhibitors targeting metallo-beta-lactamases to restore carbapenem efficacy against resistant Gram-negative bacteria.

Fungal Virulence Factor Characterization

Investigation of fungal melanin, capsule, and enzyme production as targets for antifungal drug development.

CRISPR-Based Antimicrobial Gene Editing

Development of CRISPR-Cas systems to selectively target and eliminate pathogenic microorganisms while preserving beneficial microbial communities in pharmaceutical applications.

Polymicrobial Infection Synergy Mechanisms

Investigation of cooperative pathogenic interactions between multiple microbial species and implications for antimicrobial therapy design and efficacy.

Gut Microbiome Drug Metabolism Interactions

Examination of how commensal and pathogenic bacteria metabolize pharmaceutical compounds and influence drug bioavailability and therapeutic outcomes.

Persister Cell Elimination Strategies

Design of novel therapeutic approaches targeting phenotypically resistant persister cells that survive conventional antimicrobial treatment regimens.

Antimicrobial Resistance Prediction Modeling

Development of computational and machine learning models to predict emergence and spread of antimicrobial resistance in clinical and environmental settings.

Membrane Lipid Targeting Therapeutics

Design of antimicrobial agents that disrupt microbial cell membrane lipid composition and structural integrity through novel biochemical mechanisms.

Pathogen-Associated Molecular Pattern Recognition

Investigation of pharmaceutical targeting strategies utilizing pattern recognition receptors to enhance immune response against specific microbial pathogens.

Biofilm Matrix Polymer Degradation

Development of enzymatic and chemical approaches to degrade extracellular polymeric substances in biofilms to enhance antimicrobial penetration.

Antivirulence Drug Discovery Platforms

Creation of screening methodologies and chemical libraries targeting bacterial virulence factors rather than essential survival mechanisms.

Microbial Genetic Determinant Sequencing

High-throughput genomic analysis of pathogenic microorganisms to identify novel drug targets and resistance mechanisms in clinical isolates.

Systemic Fungal Infection Pathophysiology

Study of dissemination mechanisms and organ-specific colonization patterns of invasive fungi to develop targeted antifungal interventions.

Antimicrobial Photodynamic Therapy Innovation

Development of photosensitizer compounds and light-based protocols for selective elimination of resistant microbial pathogens in pharmaceutical contexts.

Mucosal Immunity Enhancement Microbiology

Investigation of microbial adjuvants and immunogenic structures to augment mucosal immune responses against infectious agents.

Bacterial Chromosome Replication Inhibition

Design of inhibitors targeting bacterial DNA replication machinery components including DnaB helicase and primase enzymes as novel antimicrobial targets.

Pathogenic Protozoan Lifecycle Targeting

Pharmaceutical development against stage-specific protozoal antigens and metabolic requirements during different lifecycle stages of parasitic organisms.

Environmental Persistence Microbiology

Study of microbial survival mechanisms in pharmaceutical manufacturing environments and strategies to prevent environmental contamination and persistence.

Macrolide Resistance Evolution Tracking

Molecular epidemiological surveillance of macrolide-resistant pathogens to understand resistance dissemination patterns and inform therapeutic strategies.

Bacterial Ribosomal RNA Targeting

Development of antimicrobial compounds targeting specific bacterial ribosomal RNA structures to selectively inhibit pathogen protein synthesis.

Candida Species Transition Mechanisms

Investigation of morphological switching and phenotypic transitions in Candida species that confer antifungal drug resistance and virulence enhancement.

Immunopharmaceutical Microbial Conjugates

Design of immunogenic conjugates combining microbial antigens with pharmaceutical carriers to enhance targeted immune recognition and pathogen elimination.

Gram-Positive Antibiotic Target Discovery

Identification of unique metabolic and structural vulnerabilities in Gram-positive bacteria for development of selective antimicrobial agents.

Viral RNA-Dependent RNA Polymerase Inhibition

Pharmaceutical development targeting viral RNA-dependent polymerase enzymes as broad-spectrum antiviral strategy across diverse viral families.

Microbial Biomarker Detection Technologies

Creation of rapid diagnostic platforms identifying microbial biomarkers for pathogen characterization and antimicrobial susceptibility prediction.

Carbapenem Resistance Epidemiology Surveillance

Global tracking and analysis of carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa emergence and transmission patterns.

Mitochondrial-Targeting Antifungal Agents

Development of antimycotic compounds targeting fungal mitochondrial functions and oxidative phosphorylation pathways in pathogenic fungi.

Bacterial Secretion System Interference

Design of inhibitors targeting bacterial Type III, IV, and VI secretion systems that deliver virulence factors and resist immune attack.

Microbial Stress Response Exploitation

Pharmaceutical targeting of bacterial stress response pathways including SOS response and stringent response to enhance antimicrobial efficacy.

Opportunistic Infection Risk Stratification

Development of predictive models identifying immunocompromised patients at highest risk for specific opportunistic microbial infections.

Herpesvirus Latency-Associated Transcripts

Investigation of latency-associated transcripts in herpesviruses as therapeutic targets to prevent viral reactivation and recurrent infection.

Zoonotic Pathogen Spillover Prevention

Study of microbial factors facilitating zoonotic disease emergence and development of preventive pharmaceutical interventions at human-animal interfaces.

Polymyxin Colistin Resistance Mechanisms

Elucidation of emerging resistance mechanisms to last-resort antimicrobial polymyxins and strategies to overcome this critical therapeutic threat.

Microbial Metabolite Immunomodulation

Investigation of how bacterial metabolites including short-chain fatty acids influence host immune responses and infection susceptibility.

Viral Capsid Assembly Inhibition

Development of antiviral compounds targeting viral capsid protein assembly and maturation processes in diverse virus families.

Bacterial Flagella Motility Targeting

Design of antimicrobial agents inhibiting bacterial flagellar proteins and motility mechanisms that contribute to pathogenicity and dissemination.

Microbial Genetic Code Expansion Exploitation

Pharmaceutical development targeting organism-specific genetic code variations and ambiguous codon usage in pathogenic microbes.

Protease-Activated Antimicrobial Prodrugs

Creation of antimicrobial prodrugs activated by pathogen-specific proteases to achieve selective targeting and reduced systemic toxicity.

Fungal Cell Wall Chitin Targeting

Development of antifungal agents specifically targeting chitin synthesis and remodeling pathways unique to fungal organisms.

Bacterial Iron Acquisition Inhibition

Design of siderophore analogs and iron transport inhibitors to block essential iron acquisition pathways in pathogenic bacteria.

Cryptic Resistance Gene Activation Prevention

Study of mechanisms activating silent antibiotic resistance genes and development of strategies to prevent their induction under antimicrobial stress.

Viral Envelope Glycoprotein Disruption

Development of antiviral agents targeting envelope glycoprotein conformational changes and receptor binding mechanisms in enveloped viruses.

Bacterial Peptidoglycan Remodeling Inhibition

Design of inhibitors targeting penicillin-binding proteins and peptidoglycan remodeling enzymes essential for bacterial cell integrity maintenance.

Mycobacterial Lipid Metabolism Targeting

Development of antimycobacterial drugs targeting unique lipid biosynthesis pathways and lipid-rich cell wall components in Mycobacterium tuberculosis.

Parasitic Nematode Neurotransmission Blockade

Design of antiparasitic agents targeting nematode-specific neurotransmitter systems and signal transduction mechanisms.

Microbial Heteroresistance Detection Methods

Development of diagnostic technologies identifying subpopulations with elevated antimicrobial resistance within phenotypically susceptible bacterial cultures.

Respiratory Syncytial Virus Fusion Protein

Pharmaceutical development targeting RSV fusion protein to prevent viral entry and fusion with host respiratory epithelial cells.

Bacterial Stringent Response Modulation

Targeting of bacterial stringent response pathway and (p)ppGpp signaling to enhance antibiotic efficacy and prevent stress-induced resistance.

Microbial Biofilm Phenotypic Heterogeneity

Investigation of phenotypic diversity within biofilms and exploitation of heterogeneity for improved antimicrobial therapeutic strategies.

Fungal Ergosterol Biosynthesis Pathway Targeting

Development of novel antifungal compounds inhibiting specific enzymes in fungal ergosterol synthesis distinct from cholesterol pathways.

Antimicrobial Combination Synergy Prediction

Creation of mathematical and computational models predicting synergistic interactions between antimicrobial drug combinations before clinical testing.

Bacterial Chaperone-Assisted Protein Folding

Targeting of bacterial heat shock proteins and chaperones to disrupt proper folding of essential pathogenic proteins.

Polymicrobial Infection Dynamics and Interactions

Investigation of synergistic and antagonistic interactions between multiple microbial species in complex infection ecosystems.

Glycopeptide Antibiotic Resistance Mechanisms

Elucidation of vancomycin and teicoplanin resistance pathways in Gram-positive bacteria through molecular and biochemical approaches.

Microbial Biomarkers for Drug Efficacy Prediction

Identification and validation of molecular biomarkers predicting antimicrobial response and treatment outcomes in clinical isolates.

Persister Cell Formation and Eradication

Study of heterogeneous persister phenotypes that survive antibiotic exposure and development of strategies for their elimination.

Antimicrobial Photodynamic Therapy Mechanisms

Investigation of light-activated antimicrobial compounds and their photochemical interactions with pathogenic microorganisms.

Carbapenem-Resistant Enterobacteriaceae Control

Development of novel therapeutic and containment strategies targeting multidrug-resistant Gram-negative pathogens producing carbapenemases.

Antimicrobial Nanoparticle Toxicity Assessment

Comprehensive evaluation of safety profiles and off-target effects of metallic and polymeric antimicrobial nanoparticles.

Cyclic Lipopeptide Antibiotic Development

Design and optimization of cyclic lipopeptides with enhanced membrane disruption capacity and reduced toxicity profiles.

Fungal Resistance to Azole Antifungals

Characterization of molecular mechanisms underlying azole resistance in Candida and Aspergillus species through genomic and proteomic analysis.

Gut Microbiota Dysbiosis Recovery Therapeutics

Development of targeted interventions to restore healthy microbiota composition following antimicrobial-induced dysbiosis.

Aminoglycoside Nephrotoxicity Mitigation Strategies

Investigation of protective mechanisms and adjunctive therapies to reduce renal toxicity associated with aminoglycoside antibiotics.

Polymyxin Colistin Resistance Emergence

Surveillance and mechanistic studies of emerging resistance to last-resort polymyxin antibiotics in Gram-negative bacteria.

Microbial Volatile Organic Compounds Pharmacology

Characterization of antimicrobial and therapeutic properties of volatile organic compounds produced by microorganisms.

Antimicrobial Efficacy in Biofilm Microenvironments

Evaluation of antibiotic penetration and activity within spatially heterogeneous biofilm microenvironments and oxygen gradients.

Rifamycin Resistance and Structural Evolution

Study of rifamycin resistance mechanisms and design of next-generation rifamycin derivatives with expanded activity.

Bacterial Membrane Lipid Composition Targeting

Development of antimicrobials targeting essential lipid biosynthesis pathways unique to bacterial cell membranes.

Antimicrobial Tolerance and Heteroresistance

Investigation of phenotypic tolerance mechanisms allowing bacterial survival without genetic resistance mutations.

Microbial Genomic Epidemiology and Transmission

Whole-genome sequencing-based tracking of pathogenic microorganism transmission patterns and evolutionary dynamics in populations.

Proteolytic Enzyme Inhibitor Development

Design of selective inhibitors targeting bacterial and fungal proteases involved in virulence and tissue invasion.

Iron Acquisition Pathway Antimicrobial Targets

Development of antimicrobials targeting siderophore synthesis and iron uptake systems essential for pathogen survival.

Antimicrobial Adjuvant Combination Strategies

Optimization of non-antibiotic adjuvants that enhance antimicrobial efficacy through immunomodulation or resistance inhibition.

Microbial Metabolic Reprogramming Under Drug Stress

Systems-level analysis of how pathogens reprogram central metabolism in response to antimicrobial exposure.

Two-Component Regulatory System Inhibition

Design of inhibitors targeting bacterial two-component signal transduction systems controlling virulence and antibiotic resistance.

Lactic Acid Bacteria Antimicrobial Metabolites

Discovery and characterization of antimicrobial compounds produced by lactic acid bacteria for therapeutic applications.

Macrolide Resistance in Respiratory Pathogens

Investigation of macrolide resistance mechanisms in Streptococcus pneumoniae and Haemophilus influenzae with novel countermeasures.

Bacterial Lipase and Esterase Inhibitor Screening

Identification of inhibitors targeting microbial lipases and esterases involved in pathogenesis and biofilm maintenance.

Antimicrobial Textile and Surface Coatings

Development and testing of durable antimicrobial coatings for medical devices and hospital surfaces.

Microbial Small RNA Regulation Targeting

Design of antisense oligonucleotides and small molecules targeting bacterial small RNAs controlling virulence expression.

Candida Auris Resistance and Epidemiology

Comprehensive investigation of multidrug resistance mechanisms in the emerging pathogenic fungus Candida auris.

Antimicrobial Resistance Gene Detection and Quantification

Development of sensitive molecular methods for rapid identification and quantification of resistance genes in clinical samples.

Mycobacterial Cell Wall Arabinogalactan Targeting

Design of drugs targeting unique arabinogalactan biosynthesis in mycobacteria for tuberculosis and MAC treatment.

Fungal Chitin and Beta-Glucan Synthesis Inhibition

Development of novel antifungals targeting cell wall synthesis through chitin synthase and glucan synthase pathways.

Bacterial Phenotypic Susceptibility Heterogeneity

Study of population-level heterogeneity in antibiotic susceptibility within genetically identical bacterial populations.

Parasitic Protease Inhibitor Development

Design of selective inhibitors targeting parasitic proteases essential for nutrient acquisition and host cell invasion.

Antimicrobial Stability in Gastric Environments

Evaluation and enhancement of oral antimicrobial drug stability and bioavailability in variable pH gastric conditions.

Bacterial Acyl-Homoserine Lactone Degradation

Development of enzymatic and chemical approaches to degrade quorum sensing molecules and attenuate virulence.

Fungal Ergosterol Biosynthesis Modulation

Design of allosteric inhibitors and modulators of fungal-specific ergosterol synthesis for enhanced antifungal efficacy.

Microbial Infection Site Targeting Strategies

Development of targeted delivery systems for antimicrobials to specific infection sites using ligand-binding and nanoparticle approaches.

Penicillin-Binding Protein Mutations and Resistance

Structural analysis of penicillin-binding protein mutations conferring beta-lactam resistance and design of inhibitors.

Viral Protease Inhibitor Optimization

Rational design and structure-activity relationship studies of protease inhibitors for emerging viral pathogens.

Bacterial Flagellar Motor Antagonist Discovery

Identification of compounds inhibiting bacterial flagellar function to reduce motility and virulence.

Antimicrobial Synergy Prediction Models

Development of computational models predicting synergistic drug combinations based on microbial genomic and phenotypic data.

Cryptosporidium and Toxoplasma Drug Targets

Identification and validation of novel drug targets in apicomplexan parasites with reduced host toxicity.

Β-Lactamase Structural Classification and Inhibitor Design

Comprehensive structural characterization of diverse beta-lactamase families and rational design of mechanism-based inhibitors.

Vancomycin Heteroresistance in Staphylococcus aureus

Investigation of vancomycin heteroresistance mechanisms in MRSA and development of sensitizing agents.

Microbial Secondary Metabolite Biosynthesis Regulation

Study of regulatory mechanisms controlling production of antimicrobially active secondary metabolites in microorganisms.

Antimicrobial Peptide Structure-Activity Relationships

Systematic analysis of antimicrobial peptide structural determinants for enhanced bactericidal activity and reduced toxicity.

Oxazolidinone Resistance Mechanisms and Mitigation

Characterization of linezolid and tedizolid resistance pathways in Gram-positive bacteria and resistance reversal strategies.

Bacterial Cell Division Inhibitor Development

Design of inhibitors targeting FtsZ and other essential bacterial cell division proteins.

Carbapenem-Resistant Enterobacteriaceae Treatment Strategies

Research focusing on therapeutic approaches to combat carbapenem-resistant Gram-negative pathogens and their emerging resistance mechanisms.

MicroRNA Regulation of Bacterial Virulence

Investigation of how host microRNAs modulate bacterial pathogenesis and potential therapeutic targeting of these regulatory pathways.

Polymyxin Resistance Colistin Alternatives Development

Development of novel last-resort antimicrobial agents to address rising polymyxin resistance in multi-drug resistant pathogens.

Bacterial Cell Division Inhibitor Compounds

Discovery and optimization of drugs targeting bacterial cell division machinery as alternative antimicrobial mechanisms.

Cryptosporidium and Protozoan Parasite Chemotherapy

Development of pharmaceutical interventions against protozoan parasites with focus on drug-resistant strains.

Vancomycin-Resistant Enterococci Eradication Methods

Novel therapeutic and preventive strategies targeting vancomycin-resistant enterococci in clinical settings.

Mycoplasma and Atypical Pathogen Pharmacology

Study of antimicrobial drug efficacy and resistance patterns in fastidious and cell wall-deficient bacteria.

CRISPR-Based Antimicrobial Gene Therapy

Application of CRISPR technology to selectively target and eliminate pathogenic microorganisms in vivo.

Nosocomial Candida Auris Resistance Mechanisms

Characterization of emerging resistance mechanisms in the multidrug-resistant fungal pathogen Candida auris.

Antimicrobial Photodynamic Therapy Applications

Development of light-activated antimicrobial photosensitizers for treating resistant microbial infections.

Bacterial Lipid A Modification and Immunity

Investigation of lipid A structural modifications as mechanisms of immune evasion and antimicrobial resistance.

Zoonotic Coronavirus Pandemic Preparedness Drugs

Pharmaceutical development strategies for broad-spectrum antivirals against emerging zoonotic coronavirus variants.

Biofilm Microenvironment pH and Oxygenation

Study of microenvironmental conditions within biofilms and their impact on antimicrobial drug efficacy.

Helicobacter Pylori Resistance and Eradication

Investigation of emerging antibiotic resistance in Helicobacter pylori and novel combination therapy approaches.

Synergistic Drug Combination Screening Platforms

Development of high-throughput technologies to identify synergistic antimicrobial drug combinations.

RNA Aptamer Antimicrobial Therapeutics Design

Creation of RNA-based aptamers with antimicrobial properties as alternatives to conventional antibiotics.

Influenza Neuraminidase Inhibitor Resistance Evolution

Monitoring and characterization of antiviral resistance mechanisms in seasonal and pandemic influenza strains.

Multidrug Efflux Pump Structural Biology

Structural characterization of bacterial efflux pumps to enable rational design of pump-specific inhibitors.

Mycobacterium Tuberculosis Persister Cell Activation

Study of TB persister cells and strategies to reactivate them for improved pharmaceutical susceptibility.

Immunocompromised Opportunistic Infection Prophylaxis

Development of prophylactic antimicrobial regimens for immunocompromised patients with atypical pathogens.

Coronavirus Spike Protein Neutralizing Antibodies

Engineering of broadly neutralizing antibodies targeting conserved regions of coronavirus spike proteins.

Bacterial Two-Component Signal Inhibition Strategy

Development of drugs targeting bacterial two-component regulatory systems essential for pathogenesis.

Parasitic Helminths Drug Metabolism Interactions

Investigation of anthelmintic drug metabolism and pharmacokinetic interactions in parasitic nematode infections.

Antiretroviral Resistance Genotypic Prediction Models

Development of computational models predicting HIV drug resistance from viral genome sequences.

Chronic Pseudomonas Aeruginosa Lung Colonization

Pharmaceutical interventions targeting chronic Pseudomonas aeruginosa biofilm infections in cystic fibrosis patients.

Bacterial Membrane Fluidity Modulation Therapeutics

Discovery of compounds disrupting bacterial membrane integrity through fluidity alteration mechanisms.

Dengue Virus Protease Inhibitor Development

Structure-based design of inhibitors targeting dengue virus protease for antiviral therapy.

Clostridium Difficile Toxin-Targeted Therapeutics

Development of agents that neutralize or inhibit Clostridium difficile toxins in intestinal infections.

Filamentous Fungal Pathogen Host Interaction

Study of Aspergillus and other filamentous fungi virulence mechanisms and targeted antifungal strategies.

Ribosomal RNA Modification and Antibiotic Escape

Investigation of rRNA modifications enabling bacterial resistance to protein synthesis inhibitors.

Antimicrobial Copper and Metal Ion Compounds

Development of copper-based and transition metal antimicrobial agents for resistant pathogen control.

Hepatitis C Virus Polymerase Fidelity Mutations

Analysis of HCV polymerase mutations conferring antiviral drug resistance and replication escape.

Streptococcal Superantigen Immunologic Neutralization

Development of antibodies and therapeutics neutralizing streptococcal superantigens in severe infections.

Intracellular Survival Mechanism Pharmaceutical Targeting

Design of antimicrobials that penetrate host cells to target intracellular pathogens like Salmonella.

Antifungal Azole Resistance Molecular Epidemiology

Tracking and characterization of emerging azole resistance patterns in invasive fungal pathogens globally.

Bacterial Persister-Specific Drug Discovery Approaches

Development of screening methods and compounds specifically active against antibiotic-tolerant persister bacteria.

Polycystic Kidney Disease Cyst Infection Treatment

Pharmaceutical development for treating infections within renal cysts in autosomal dominant polycystic kidney disease.

Mycobacterium Abscessus Rapid Growing Resistance

Investigation of rapid antimicrobial resistance development in Mycobacterium abscessus non-tuberculous mycobacteria.

Phage-Antibiotic Synergy Enhancement Mechanisms

Study of how bacteriophages enhance antimicrobial efficacy and strategies for therapeutic combination.

Macrolide-Resistant Respiratory Pathogen Therapeutics

Development of alternative therapies for macrolide-resistant Streptococcus pneumoniae and atypical respiratory pathogens.

Bacterial Lipoteichoic Acid Immunotherapy Targeting

Design of therapeutics that neutralize lipoteichoic acid pathogen-associated molecular patterns.

Tuberculosis Treatment-Resistant Disease Management

Development of novel drug regimens for extensively drug-resistant and treatment-resistant tuberculosis cases.

Ornithine Decarboxylase Polyamine Antimicrobial Therapy

Targeting polyamine biosynthesis pathways in pathogens as novel antimicrobial intervention strategy.

Enterovirus Protease 2A Inhibitor Compounds

Discovery of compounds inhibiting enterovirus protease 2A for broad-spectrum antiviral applications.

Wound Microbiome Dysbiosis and Healing Impairment

Investigation of chronic wound microbiota dysbiosis and pharmaceutical interventions to restore eubiosis.

Bacterial Flagellar Motor Protein Inhibition

Development of inhibitors targeting bacterial flagellar motors to reduce motility and virulence.

Coccidioidal Spherule Wall Antigen Targeting

Design of therapeutics targeting unique spherule wall antigens of Coccidioides dimorphic fungi.

Carbonic Anhydrase Fungal Enzyme Inhibition

Development of fungal carbonic anhydrase inhibitors as antifungal agents with reduced mammalian toxicity.

Plasmodium Dihydrofolate Reductase Triple Mutants

Study of multi-mutant Plasmodium DHFR variants and strategies for overcoming antimalarial resistance.

Microbiota-Derived Metabolite Antimicrobial Activity

This research investigates how secondary metabolites produced by commensal microorganisms inhibit pathogenic bacteria and fungi, with applications in developing novel therapeutics derived from microbiota-host symbiosis.

CRISPR-Based Antimicrobial Gene Editing Therapeutics

This field explores the development and optimization of CRISPR-Cas systems as precision antimicrobial tools to selectively target and disable resistance genes or virulence factors in pathogenic microorganisms.